COPA-DATA GmbH and Prozesstechnik Kropf GmbH are supporting Hof University of Applied Sciences in Germany as platinum sponsors of their entry into "Formula Student Germany" (FSG), an international construction competition for students that has been organized by the VDI Verein Deutscher Ingenieure e.V. (Association of German Engineers) since 2006.
Whilst having many positive attributes, the proposed revisions to the regulation of fluorinated greenhouse gases (F-Gases) currently going through the co-decision procedure in Europe will have a significant impact on the application of F-Gases for medical uses.
Medelpharm, known for its innovative technologies in powder compression for the pharmaceutical, chemical and nutrition industry, have announced their presence at Cifa, SIPEC and AAPS exhibitions this winter.
Nominees are PHT Corporation, for driving eClinical research innovation; PHT President and CEO Philip Lee, for advancing the eCOA industry; the LogPad App™, for collecting clinical research data from any smartphone; and the PHT recruiting video
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, announces the acquisition by Hybrigenics Services, its subsidiary specialized in protein interactions, of the yeast two-hybrid (Y2H) activities of Dualsystems Biotech, a privately owned Swiss company based in Schlieren near Zurich. Financial terms are not disclosed and will not involve the issuance of any Hybrigenics shares.
The Electrospinning Company has supplied biodegradable, synthetic electrospun membranes to a team led by Professor Sheila MacNeil of the University of Sheffield, who are developing affordable corneal surface regeneration techniques in collaboration with experts in India.
September 2013 sees the welcome return of the 12th Annual Pharmaceutical Packaging & Labelling conference; Providing a platform for industry leaders, innovators and decision makers to meet, discuss and showcase vital strategies important to maintain grow and expand an industry facing tougher regulations relating to the packaging & labelling of pharmaceutical products.
Glycotope GmbH, a global leader in optimizing the glycosylation of biopharmaceuticals, announced today that the Company completed randomization of patients on June 13th, 2013 in the Phase II clinical trial of its glycooptimized and fully human therapeutic protein FSH-GEXTM (follicle-stimulating hormone) to treat women undergoing intra-cytoplasmic sperm injection (ICSI) therapy.
Glycotope GmbH, a global leader in optimizing the sugar chains (glycosylation) of biopharmaceuticals, announced full details of first-in-man Phase I trial data for CetuGEX™, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) with optimized and fully human glycosylation for a greatly enhanced anti-tumor activity and reduced side-effects. The data was presented at ASCO 2013 in the Developmental Therapeutics and Immunotherapy Session.
The new website showcases information and resources to promote the business, science, and regulatory benefits of adopting PRO and eCOA technologies in clinical research programs that collect patient data.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.